Annals of Oncology : Official Journal of the European Society for Medical Oncology

PURPOSE: In Testicular Cancer Survivors (TCSs, Diagnosis 1980-1994) to describe the prevalence of self-reported Adverse Health Outcomes (AHOs), AHO changes and their effect on Health-Related Quality of Life (HrQoL), assessed at two survey waves median 12 and 28 years after surgery-only or platinum-based chemotherapy (PBCT)."Typical AHOs" (peripheral sensory neuropathy [PSN], Raynaud phenomena [RP], tinnitus, hearing loss [HL]) were emphasized. PATIENTS AND METHOD: 427 TCSs were evaluable: Surgery-Only (n: 155), PBCT-Standard: ≤850 mg cisplatin (n: 222), PBCT-High: >850 mg cisplatin (n: 50)...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

The 18th St. Gallen International Breast Cancer Conference held in March 2023, in Vienna, Austria, assessed significant new findings for local and systemic therapies for early breast cancer with a focus on the evaluation of multimodal treatment options. The emergence of more effective, innovative agents in both the preoperative (primary, or neoadjuvant) and postoperative (adjuvant) settings, has underscored the pivotal role of a multidisciplinary approach in treatment decision-making, particularly when selecting systemic therapy for an individual patient...

INTRODUCTION: This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over median follow-up of approximately 2 years from EV-301. MATERIALS AND METHODS: Patients with locally advanced/metastatic urothelial carcinoma with prior platinum-containing chemotherapy and disease progression during/after programmed cell death protein 1/ligand 1 inhibitor treatment were randomized to enfortumab vedotin or chemotherapy (docetaxel, paclitaxel, vinflunine)...

No abstract text is available yet for this article.

BACKGROUND: The phase III MONALEESA trials tested the efficacy and safety of the CDK4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of HR+/HER2- advanced breast cancer. Using the largest pooled biomarker dataset of the CDK4/6 inhibitor ribociclib in advanced breast cancer to date, we identified potential biomarkers of response to ribociclib. PATIENTS AND METHODS: Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing...

BACKGROUND: Relapsed or refractory peripheral T cell lymphomas (r/r PTCLs) are a group of rare and aggressive diseases, which lack effective therapies. Constitutive activation of Janus kinase (JAK)/signal transducer and activation of transcription (STAT) pathway are reported to be associated with PTCLs. Golidocitinib is an oral, potent JAK1 selective inhibitor evaluated in a phase 1/2 multinational study in r/r PTCLs. PATIENTS AND METHODS: Patients with r/r PTCLs were eligible...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: The optimal time to surgery after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested better outcomes, especially in terms of histological response, after prolonged delay of up to three months after nCRT. The NeoRes II trial is the first randomised trial to compare standard to prolonged time to surgery after nCRT for oesophageal cancer. PATIENTS AND METHODS: Patients with resectable, locally advanced oesophageal cancer were randomly assigned to standard delay of surgery of 4-6 weeks or prolonged delay of 10-12 weeks after nCRT...

BACKGROUND: HER2-low is a newly defined category with HER2 1+ or 2+ expression by immunohistochemistry (IHC) and lack of HER2 gene amplification measured by in situ hybridization (ISH). Much remains unknown about the HER2-low status across tumor types and changes in HER2 status between primary and metastatic samples. METHODS: HER2 expression by IHC was evaluated in 4,701 patients with solid tumors. We have evaluated the HER2 expression by IHC and amplification by ISH in paired breast and gastric/gastroesophageal (GEJ) primary and metastatic samples...

BACKGROUND: The prognostic value of KRAS and BRAFV600E mutations in stage III CC remains controversial and has never been clearly analyzed in patients with MSI-H tumors due to sample size limitations. Data are also lacking for KRAS sub-mutations and prognosis. METHODS: We examined clinicopathological variables and prognosis in surgically resected stage III CC patients who participated in 7 clinical trials from the ACCENT/IDEA databases Associations between KRAS exon 2 and BRAFV600E mutations and time to recurrence (TTR), overall survival (OS), and survival after recurrence (SAR) were assessed by Cox model...

No abstract text is available yet for this article.

BACKGROUND: We aimed to examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAT). PATIENTS AND METHODS: We identified responders (RCB-0/1) and matched non-responders (RCB-2/3) from the phase II TBCRC 030 prospective study of neoadjuvant paclitaxel vs. cisplatin in TNBC. We collected plasma samples at baseline, three weeks, and twelve weeks (end of therapy)...

BACKGROUND: HER2 mutations are targetable alterations in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib+fulvestrant, or neratinib+fulvestrant+trastuzumab (N+F+T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (7 in each arm) from a randomized substudy of fulvestrant versus fulvestrant+trastuzumab (F+T) versus N+F+T. PATIENTS AND METHODS: Patients with HR+ HER2-negative MBC with activating HER2 mutation(s) and prior CDK4/6 inhibitor therapy received N+F+T (oral neratinib 240 mg/d with loperamide prophylaxis, intramuscular fulvestrant 500 mg days 1, 15, 29 of cycle 1 then q4w, intravenous trastuzumab 8 mg/kg then 6 mg/kg q3w) or F+T or fulvestrant alone...

No abstract text is available yet for this article.

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline...

No abstract text is available yet for this article.

PURPOSE: Patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICB) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. METHODS: ATALANTE-1 was a two-step open-label study, to evaluate the efficacy and safety of OSE2101 compared to standard of care (SoC) chemotherapy (CT)...